



(86) Date de dépôt PCT/PCT Filing Date: 2004/09/01  
(87) Date publication PCT/PCT Publication Date: 2005/03/17  
(85) Entrée phase nationale/National Entry: 2006/02/15  
(86) N° demande PCT/PCT Application No.: SE 2004/001259  
(87) N° publication PCT/PCT Publication No.: 2005/023797  
(30) Priorité/Priority: 2003/09/04 (SE0302382-7)

(51) Cl.Int./Int.Cl. *C07D 401/12* (2006.01),  
*C07C 211/38* (2006.01), *A61P 1/04* (2006.01),  
*A61K 31/4439* (2006.01)

(71) Demandeur/Applicant:  
ASTRAZENECA AB, SE

(72) Inventeurs/Inventors:  
DAHLSTROEM, MIKAEL, SE;  
LINDQVIST, BO, SE

(74) Agent: FETHERSTONHAUGH & CO.

(54) Titre : NOUVEAUX SELS D'OMEPRAZOLE ET D'ESOMEPRAZOLE II  
(54) Title: NEW SALTS OF OMEPRAZOLE AND ESOMEPRAZOLE II

(57) **Abrégé/Abstract:**

The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (S)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((S)-omeprazole) and (R)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole ((R)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (S)-omeprazole and (R)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.



## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
17 March 2005 (17.03.2005)

PCT

(10) International Publication Number  
**WO 2005/023797 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 401/12**,  
A61K 31/4439, C07C 211/38, A61P 1/04

TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(21) International Application Number:  
PCT/SE2004/001259

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(22) International Filing Date:  
1 September 2004 (01.09.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0302382-7 4 September 2003 (04.09.2003) SE

(71) Applicant (*for all designated States except US*): **ASTRAZENECA AB** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **DAHLSTRÖM, Mikael** [FI/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). **LINDQVIST, Bo** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,

#### Declaration under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

#### Published:

— *with international search report*  
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: NEW SALTS OF OMEPRAZOLE AND ESOMEPRAZOLE II

(57) Abstract: The present invention relates to new salts of the single enantiomers of omeprazole, i.e. salts of (*S*)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole ((*S*)-omeprazole) and (*R*)-5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole ((*R*)-omeprazole) respectively. More specifically, the present invention relates to 1-cyclohexylethyl ammonium salts of the compounds, formed by a reaction of (*S*)-omeprazole and (*R*)-omeprazole respectively and 1-cyclohexylethyl amine. The present invention also relates to a process for preparing the compounds of the invention, a pharmaceutical preparation and a method for treatment of gastric related disorders by administering the compounds of the invention.

WO 2005/023797 A1



## New salts of omeprazole and esomeprazole II.

### *Field of the Invention*

5 The present invention relates to novel salts of the single enantiomers of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (omeprazole) in a pure and isolated form. Specifically, it relates to 1-cyclohexylethyl ammonium salts of the single enantiomers of omeprazole. The present invention also relates to processes for preparing the 1-cyclohexylethyl ammonium salts of the single enantiomers of omeprazole  
10 in a pure and isolated form and pharmaceutical compositions containing them.

### *Background of the invention and prior art*

The compound 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-  
15 benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 0 005 129.

Omeprazole is a sulfoxide and a chiral compound, wherein the sulphur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers,  
20 the (*R*)- and (*S*)-enantiomer of omeprazole, herein referred to as (*R*)-omeprazole and (*S*)-omeprazole, the latter have the generic name esomeprazole. The absolute configuration of the enantiomers of omeprazole has been determined by an X-ray study of an N-alkylated derivative of the (*R*)-enantiomer.

25 Omeprazole and its single enantiomers are proton pump inhibitors, and are useful as antiulcer agents. In a more general sense, omeprazole may be used for prevention and treatment of gastric acid related diseases in mammals and especially in man.

Specific alkaline salts of omeprazole are disclosed in EP 0 124 495. Herein, quaternary ammonium salts and guanidine salts of omeprazole are disclosed. Document WO 97/41114  
30 discloses processes for preparing magnesium salt of benzimidazoles, including magnesium

salt of omeprazole. However, no salts of omeprazole or its single enantiomers prepared from a primary amine, such as 1-cyclohexyl ethyl amine, are mentioned in these documents.

5 Certain salts of the single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988, for instance, quaternary ammonium salts of esomeprazole are mentioned. However, no salts employing primary, secondary or tertiary amines are disclosed or suggested. The described salts of esomeprazole have improved pharmacokinetic and metabolic properties, which will give an improved therapeutic profile such as a lower  
10 degree of interindividual variation. WO 96/02535 and WO 98/54171 disclose preferred processes for preparing esomeprazole and salts thereof. Further, primary amine salts are described in WO 03/074514.

In the formulation of drug compositions, it is important for the active pharmaceutical  
15 ingredient to be in a form in which it can be conveniently handled and processed. This is of importance, not only from the point of view of obtaining a commercially viable manufacturing process, but also from the point of view of subsequent manufacture of pharmaceutical formulations (e.g. oral dosage forms such as tablets) comprising the active pharmaceutical ingredient.

20

Further, in the manufacture of oral pharmaceutical compositions, it is important that a reliable, reproducible and constant plasma concentration profile of the active pharmaceutical ingredient is provided following administration to a patient.

25 Chemical stability, solid state stability, and "shelf life" of the active pharmaceutical ingredient are important properties for a pharmaceutical active compound. The active pharmaceutical ingredient, and compositions containing it, should be capable of being effectively stored over appreciable periods of time, without exhibiting a significant change in the physico-chemical characteristics of the active pharmaceutical ingredient, e.g. its  
30 chemical composition, density, hygroscopicity and solubility. Thus, in the manufacture of



commercially viable and pharmaceutically acceptable drug compositions, it is important, wherever possible, to provide the active pharmaceutical ingredient in a crystalline and stable form.


## 5 *Drawings*

Figure 1 is an X-ray powder diffractogram of the (*R*)-1-cyclohexylethyl ammonium salt of (*S*)-omeprazole.

## 10 *Description of the invention*

The present invention refers to new 1-cyclohexylethyl ammonium salts having the following formula I including compounds Ia and Ib:

15



Formula Ia: 1-cyclohexylethyl ammonium salts of the (*S*)-enantiomer of omeprazole

20

Formula Ib: 1-cyclohexylethyl ammonium salts of the (*R*)-enantiomer of omeprazole

wherein R is defined as the 1-cyclohexylethyl group. The 1-cyclohexylethyl amine is a chiral compound, including (*S*)-1-cyclohexylethyl amine and (*R*)-1-cyclohexyl ethyl amine.

25

The chemical name (*R*)-5-methoxy-2-[[*(4*-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (*S*)-1-cyclohexylethyl ammonium salt as well as the chemical name (*S*)-5-methoxy-2-[[*(4*-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole (*R*)-1-cyclohexylethyl ammonium salt does not necessarily mean that  
 5 the methoxy group of the benzimidazole moieties is in the 5-position but may as well be in the 6-position, or there may be mixtures thereof.

Another embodiment of the invention is the (*R*)-5-methoxy-2-[[*(4*-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole (*S*)-1-cyclohexylethyl ammonium salt.

10

The compounds of the invention may be prepared in the form of solvates, hydrates, and anhydrides.

In a further aspect, the present invention provides processes for the preparation of 1-  
 15 cyclohexylethyl ammonium salts of omeprazole and of esomeprazole. It has surprisingly been found that 1-cyclohexylethyl ammonium salts of the (*R*)- and (*S*)-enantiomers of omeprazole may be obtained in a well-defined crystalline state.

Another embodiment of the invention is the (*S*)-5-methoxy-2-[[*(4*-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1*H*-benzimidazole (*R*)-1-cyclohexylethyl ammonium salt.

20

This compound of the invention is characterized in providing an X-ray powder diffraction pattern, as in figure 1, exhibiting substantially the following d-values and intensities:

d-value (Å)	Relative intensity	d-value (Å)	Relative intensity	d-value (Å)	Relative intensity
16.3	s	5.1	m	3.75	m
11.2	s	4.89	m	3.66	s
9.1	s	4.83	s	3.49	w
8.1	m	4.56	s	3.44	w

6.7	m	4.34	w	3.25	w
6.5	m	4.25	m	3.15	w
6.2	s	4.17	m	3.10	w
5.3	m	4.07	m	2.90	m
5.2	s	3.79	s	2.86	w

The peaks, identified with d-values calculated from the Bragg formula and intensities, have been extracted from the diffractogram of (*R*)-1-cyclohexylethyl ammonium salt of (*S*)-omeprazole.

5

The relative intensities are less reliable and instead of numerical values, the relative intensities corresponding for the peaks are denoted being strong (s), medium (m), or weak (w).

10 In addition to the peaks indicated in the table the diffractogram contains a number of very weak peaks.

The relative intensities are derived from the diffractograms measured with variable slits. The XRPD distance values may vary in the range of  $\pm 2$  on the last decimal place.

15

X-ray powder diffraction (XRPD) analysis was performed on sample of (*R*)-1-cyclohexylethyl ammonium salt of (*S*)-omeprazole, according to standard methods, for example, those described in Giacobazzo, C. et al. (1995), Fundamentals of Crystallography, Oxford University Press; Jenkins, R. and Snyder, R. L. (1996),  
 20 Introduction to X-Ray Powder Diffractometry, John Wiley & Sons, New York; Bunn, C. W. (1948), Chemical Crystallography, Clarendon Press, London; or Klug, H. P. & Alexander, L. E. (1974), X-ray Diffraction Procedures, John Wiley and Sons, New York. X-ray analyses were performed using a Siemens D5000 diffractometer.



The compounds of the invention are characterized by the positions and intensities of the peaks in the X-ray powder diffractogram. Furthermore, the compounds of the invention could be characterized by  $^1\text{H}$ -NMR, IR, FTIR and Raman spectroscopy.

5 In a further aspect, the present invention provides processes for the preparation of 1-cyclohexylethyl ammonium salts of (*R*)-omeprazole and of (*S*)-omeprazole. Suitable processes for the salt formation are temperature induced crystallisation, fast crystallisation at elevated temperature, slow crystallisation at room temperature, thermal recrystallisation, antisolvent induced crystallisation, and crystallisation by evaporation.

10

In a further aspect, the present invention provides processes for the preparation of 1-cyclohexylethyl ammonium salts of the enantiomers of omeprazole, (*R*)- and (*S*)-omeprazole, which comprises the following steps: (*R*)-omeprazole or (*S*)-omeprazole is either dissolved or formed *in situ* in a suitable solvent, such as acetonitril, ethyl acetate or  
15 *tert*-butyl methyl ether, either alone or in mixture with methanol. The 1-cyclohexylethyl amine is added during stirring. A precipitate of the salt compound is formed and the precipitate is separated by filtration. The obtained compound is washed with a solvent and the obtained crystals are dried.

20 Still a further aspect of the invention is that the novel compounds may be of interest as intermediates in the synthesis of other compounds such as magnesium salts of omeprazole and of esomeprazole, which are the pharmaceutically active components in products with the tradenames Losec<sup>®</sup> MUPS<sup>®</sup> and Nexium<sup>®</sup>. During the synthesis of the active component for Nexium<sup>®</sup> i.e. the magnesium salt of esomeprazole, a titanium catalyst may  
25 be used in the oxidation step prior to the salt formation steps. The synthesis usually proceeds with the formation of monovalent salt of esomeprazole by adding a monovalent hydroxide or alkoxide. This monovalent salt of esomeprazole, such as sodium or potassium salts, is thereafter converted to the magnesium salt. Insoluble inorganic titanium salts, such as titanium oxid, are being formed when strong bases such as sodium or potassium  
30 alkoxides are being added to a solution of titanium catalysts. Using 1-cyclohexylethyl



amine as a salt forming agent rather than using a sodium- or potassium-containing base avoids the risk of inorganic titanium salts being co-precipitated with the desired salt. Even, if the titanium-catalyst may react with the 1-cyclohexylethyl amine, a soluble complex of the 1-cyclohexylethyl amine and titanium may be formed, which may stay in the solution while filtering off the desired 1-cyclohexylethyl ammonium salt of the benzimidazole compound.

Solutions containing the dissolved and ionised alkylammonium salt of omeprazole or alkylammonium salt of esomeprazole have a lower pH than corresponding solutions made from the previously known alkali-salts of omeprazole and of esomeprazole, less basic solutions are advantageous for intravenous administration.

The exemplified (*R*)-1-cyclohexyl ethyl ammonium salt of (*S*)-omeprazole, is in crystalline form. The salt exhibits advantageous properties, such as convenient handling as well as chemical and solid-state stability. The products obtained according to the present invention are well-defined crystalline products. Such crystalline products give an easily processability during the manufacture of suitable dosage forms. A crystalline product is easy to handle during milling, filtering and tableting. The procedures have high reproducibility. Also, the stability is improved when a well-defined crystalline form of the compound is obtained. These properties are of great value considering dosage forms such as e.g. tablets.

These active substances are useful for inhibiting gastric acid secretion in mammals and man. In a more general sense, they may be used for prevention and treatment of gastric acid related diseases in mammals and man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID (non steroidal anti inflammatory drug) therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic and non-symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in

intensive care situations, in patients with acute upper gastrointestinal bleeding, pre-and postoperatively to prevent acid aspiration of gastric acid and to prevent and treat stress ulceration. Further, they may be useful for prevention and treatment of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), ulcerative colitis and Crohn's disease,  
5 asthma, laryngitis, Barret's syndrome, sleep apnea, sleep disturbance, psoriasis as well as being useful for prevention and treatment of Helicobacter infections and diseases related to the above conditions.

For the avoidance of doubt, by "treatment" is meant to include the therapeutic treatment as  
10 well as the prophylaxis, of a condition.

Any suitable route of administration may be employed for providing the patient with an effective dosage of the 1-cyclohexylethyl ammonium salt of (*R*)-omeprazole and of (*S*)-omeprazole, according to the invention. For example, peroral or parenteral formulations  
15 and the like may be employed. Dosage forms include capsules, tablets, dispersions, suspensions and the like.

It is further provided a pharmaceutical composition comprising the compounds according to the invention, as active ingredient, in association with a pharmaceutically acceptable  
20 carrier, diluent or excipient and optionally other therapeutic ingredients. Compositions comprising other therapeutic ingredients are especially of interest in the treatment of Helicobacter infections. The invention also provides the use of the compounds in the manufacture of a medicament for use in the treatment of a gastric-acid related condition and a method of treating a gastric-acid related condition which method comprises  
25 administering to a subject suffering from said condition a therapeutically effective amount of the compounds according to the invention.

The composition of the invention includes compositions suitable for peroral or parenteral administration. The most preferred route is the oral route. The compositions may be



conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.

In the practice of the invention, the most suitable route of administration as well as the  
5 magnitude of a therapeutic dose of the compounds according to the invention in any case  
will depend on the nature and severity of the disease to be treated. The dose, and dose  
frequency, may also vary according to the age, body weight and response of the individual  
patient. Special requirements may be needed for patients having Zollinger-Ellison  
10 syndrome, such as a need for higher doses than the average patient. Children and patients  
with liver diseases generally will benefit from doses that are somewhat lower than average.  
Thus, in some conditions it may be necessary to use doses outside the ranges stated below,  
for example long-term treatments may request lower dosage. Such higher and lower doses  
are within the scope of the present invention. Such daily doses may vary between 5 mg to  
300 mg.

15

In general, a suitable oral dosage form of the compound of the invention may cover a dose  
range from 5 mg to 300 mg total daily dose, administered in one single dose or equally  
divided doses. A preferred dosage range is from 10 mg to 80 mg.

20 The compound of the invention may be combined as the active component in intimate  
admixture with a pharmaceutical carrier according to conventional techniques, such as the  
oral formulations described in WO 96/01623 and EP 0 247 983, the disclosures of which  
are hereby as a whole included by reference.

25 Combination preparations comprising the compounds of the invention and other active  
ingredients may also be used. Examples of such active ingredients include, but are not  
limited to anti-bacterial compounds, non-steroidal anti-inflammatory agents (including  
acetylsalicylic acid), antacid agents, alginates, prokinetic agents, bisfosfonates, histamine  
H<sub>2</sub>-receptor antagonists, and GABA<sub>B</sub> agonists such as baclofen and those disclosed in WO  
30 01/42252 and WO 01/41743.

The examples below will further illustrate the preparation of the compound of the invention, according to different process routes and including new intermediates. These examples are not intended to limit the scope of the invention as defined hereinabove or as  
5 claimed below.



*Examples*

Example 1: (*S*)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (*R*)-1-cyclohexylethyl ammonium salt

5

(*S*)-omeprazole (1.0 g, 2.9 mmol) was dissolved in acetonitrile (10 ml). (*R*)-1-cyclohexylethyl amine (0.83 ml, 5.7 mmol) was added to the solution whereupon a white solid precipitated. After 45 minutes acetonitrile (10 ml) was added to the thick reaction mass and stirring was continued for 45 minutes. The precipitate was filtered off, washed with  
10 acetonitrile, and dried. 0.5 g of the title compound was obtained.

15

<sup>1</sup>H-NMR (400 MHz, CD<sub>3</sub> OD) : 0.93-1.06 (m, 2H), 1.1 (d, 3H), 1.12-1.34 (m, 4H), 1.64-1.83 (m, 5H), 2.13 (s, 3H), 2.23 (s, 3H), 2.76 (quintet 1H), 3.67 (s, 3H), 3.83 (s, 3H), 4.67 (d, 1H), 4.81 (d, 1H), 6.88-6.93 (dd, 1H), 7.07-7.11 (d, 1H), 7.46-7.52 (d, 1H), 8.12 (s, 1H)

Example 2: (*S*)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole (*R*)-1-cyclohexylethyl ammonium salt.

20

(*S*)-omeprazole (1.0 g, 2.9 mmol) was dissolved in ethyl acetate (10 ml). (*R*)-1-cyclohexylethylamine (0.83 ml, 5.7 mmol) was added to the solution. The obtained clear solution was seeded whereupon a white solid precipitated. After 40 minutes ethyl acetate (5 ml) was added to the thick reaction mass and stirring was continued for 10 minutes. The precipitate was filtered off, washed with acetonitrile, and dried. 0.5 g of the title compound was obtained.

25

The prepared compound was analysed by XRPD resulting in the diffractogram shown in Figure 1.

30

*Claims*

1. A 1-cyclohexyl ethyl ammonium salt of (*R*)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole ((*R*)-omeprazole) and of (*S*)-5-methoxy-2-[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1*H*-benzimidazole ((*S*)-omeprazole).
2. The 1-cyclohexylethyl ammonium salt according to claim 1 wherein the salt is (*R*)-1-cyclohexylethyl ammonium salt of (*S*)-omeprazole.
3. The 1-cyclohexylethyl ammonium salts according to any of the claims 1 and 2 characterized in that the compound is crystalline.
4. A process for preparation of 1-cyclohexylethyl ammonium salt of (*S*)-omeprazole or (*R*)-omeprazole, according to any of claims 1 to 3, which comprises the following steps:
  - a) dissolving of (*S*)-omeprazole or (*R*)-omeprazole in an organic solvent;
  - b) adding a single enantiomer of 1-cyclohexylethyl amine and precipitating the desired salt;
  - c) isolating and drying of the obtained salt of (*S*)-omeprazole or (*R*)-omeprazole .
5. The process according to claim 4 wherein the organic solvent is selected from acetonitril, ethylacetate, *tert*-butyl methyl ether, and a mixture of *tert*-butyl methyl ether and methanol.
6. The process according to claim 4 wherein the organic solvent is selected from acetonitril and ethylacetate.
7. The process according to any of claims 4 to 6 wherein an (*R*)-1-cyclohexylethyl ammonium salt of (*S*)-omeprazole is obtained.




8. The process according to any of claims 4 to 6 wherein an (*S*)-1-cyclohexylethyl ammonium salt of (*R*)-omeprazole is obtained.

9. A pharmaceutical composition comprising the 1-cyclohexylethyl ammonium salt  
5 of (*S*)-omeprazole according to any of claims 1 to 3 as active ingredients in association with pharmaceutically acceptable excipients and optionally other therapeutic ingredients.

10. Use of the 1-cyclohexylethyl ammonium salt of (*S*)-omeprazole according to any  
10 of claims 1 to 3 for the manufacture of a medicament for use in the treatment of gastric acid related condition.

11. A method for treatment of a gastric acid related condition which method  
comprised administering to a subject suffering from said condition a therapeutically  
effective amount of the 1-cyclohexylethyl ammonium salt of (*S*)-omeprazole according to  
15 any of claims 1 to 3.

1/1

*Figure 1*